Assenagon Asset Management
SYRS

Assenagon Asset Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Assenagon Asset Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,873
Closed -$81.9K – 1500
2024
Q2 		$81.9K Sell
15,873
-154,126
-91% -$810K ﹤0.01% 1393
2024
Q1 		$909K Buy
169,999
+144,869
+576% +$1M ﹤0.01% 1080
2023
Q4 		$196K Hold
25,130
– – ﹤0.01% 1372
2023
Q3 		$99.3K Buy
25,130
+14,754
+142% +$55.2K ﹤0.01% 1355
2023
Q2 		$32.7K Hold
10,376
– – ﹤0.01% 1310
2023
Q1 		$27.7K Buy
+10,376
New +$40.2K ﹤0.01% 1395
2021
Q4 		– Sell
-8,707
Closed -$389K – 1588
2021
Q3 		$389K Sell
8,707
-2,872
-25% -$140K ﹤0.01% 1100
2021
Q2 		$631K Buy
+11,579
New +$685K ﹤0.01% 997
2019
Q2 		– Sell
-3,450
Closed -$315K – 1196
2019
Q1 		$315K Sell
3,450
-5,570
-62% -$388K ﹤0.01% 859
2018
Q4 		$502K Buy
+9,020
New +$685K 0.01% 818

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Assenagon Asset Management's SYRS Position: Q3 2024 in Review

Assenagon Asset Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 15,873 shares — an estimated $81.9K sold.

Assenagon Asset Management first reported a position in SYRS in Q4 2018 and held it in 10 quarters. The position peaked at $909K in Q1 2024. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

  • Assenagon Asset Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Assenagon Asset Management sold 15,873 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $81.9K.
  • Assenagon Asset Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 10 quarters.
  • Assenagon Asset Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $909K in Q1 2024.
  • 65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Assenagon Asset Management's 13F filing for Q3 2024, filed 23 Oct 2024.